NCT01251861 2026-03-18
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01200810 2017-12-02
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666666 2014-12-18
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00348998 2013-11-06
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003517 2013-07-10
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00512668 2013-01-07
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Terminated